Product Overview
Sulphachlorpyridazine, HRP conjugate
Target
Sulfamethoxypyridazine
Storage
2-8°C short term, -20°C long term
Introduction
Sulfamethoxypyridazine, has been introduced into clinical usage which differs in several respects from currently available preparations of this group of drugs.1 The new agent is promptly absorbed after oral administration, and the free form of the drug is very slowly excreted in the urine. This results in long-sustained high plasma concentrations of free drug with doses much lower than those required to attain similar concentrations with several other sulfonamide agents.
Antigen Description
Sulfamethoxypyridazine, has been introduced into clinical usage which differs in several respects from currently available preparations of this group of drugs.1 The new agent is promptly absorbed after oral administration, and the free form of the drug is very slowly excreted in the urine. This results in long-sustained high plasma concentrations of free drug with doses much lower than those required to attain similar concentrations with several other sulfonamide agents.
Keywords
Sulfamethoxypyridazine; 4-amino-N-(6-methoxypyridazin-3-yl)benzenesulfonamide; Vinces; N1-(6-methoxypyridazin-3-yl)sulphanilamide; Altezol Benzenesulfonamide, 4-amino-N-(6-methoxy-3-pyridazinyl)-; CL 13494; Durox; Kineks; Lederkyn; Lentac; Midikel; Myasu
Citations
Publication ()
Have you cited DAG1296 in a publication?
Let us know and earn a reward for your research.
COA
Loading ......
